TEST:

SafeSEQ HPV Test

Furthermore, HPV ctDNA but not HPV16 E6 antibody levels were positively associated with disease burden as determined by N-category, overall stage, and by tumor volume (ctDNA vs. volume, r = 0.48 p = 6.4e-12; E6 vs. volume, r = -0.079 p = 0.26). Overall, this is the largest cohort to compare HPV serology and HPV ctDNA results in OPC, and these findings highlight the potential for ctDNA to augment future strategies for blood-based early detection of HPV+ OPC.

In univariate and multivariate analyzes, dynamic changes in plasma HPV ctDNA were an independent factor for predicting early treatment outcome. These findings indicate that longitudinal HPV ctDNA monitoring reflects the efficacy of CCRT in locally advanced cervical cancer and provides a basis for earlier identification of candidates for post-CCRT treatment intensive and prognostic stratification.

This ultra-sensitive HPV profiling method with optimal analytical performance may represent a significant advancement in risk stratification, treatment management, and post-treatment surveillance for patients with OPSCC.

Rapid early clearance of ctHPV-DNA during neoadjuvant therapy demonstrates utility in predicting response to treatment. Detectable ctHPV-DNA following treatment is predictive of both disease recurrence and worse survival.

"Sysmex Inostics...is proud to announce its participation at the AACR Special Conference in Cancer Research: Liquid Biopsy: From Discovery to Clinical Implementation, taking place on November 13-16, 2024 (San Diego, CA). Sysmex Inostics will be presenting two groundbreaking posters emphasizing clinical utility of HPV-SEQ, our commercially available next-generation sequencing (NGS) assay performed in a CLIA validated lab. The HPV-SEQ assay detects cell-free HPV DNA, enabling monitoring of treatment response and surveillance in HPV-related oropharyngeal cancer."

"Sysmex Inostics Inc...in collaboration with the University of Chicago Medicine announces the publication of results from the OPTIMAII trial in JAMA Oncology. Circulating tumor HPV-DNA (ctHPV-DNA) clearance, monitored using HPV-SEQ assay, predicts improved survival in patients with HPV-associated oropharyngeal cancer following nivolumab-based neoadjuvant therapy."

No abstracts available

The RaDaR assay but not CAPP-seq may detect MRD in patients who relapse within 1 year. HPV-seq may be more sensitive than dPCR for MRD detection.

The level of HPV16 ctDNA but not HPV16 E6 antibodies in plasma was associated with disease burden. These findings have potential implications for early detection and prognostication.